BONE TARGETED DRUG DELIVERY
MUSCULOSKELETAL NANOMEDICINE
Meet The Team
Seth Harlem
cofounder & CEO
Mo Chen, PhD, MBA
cofounder & Chief Science Officer
Edward Puzas, PhD
Wakenda Tyler, MD
Service Chief, Orthopaedic Oncology
Columbia University Medical Center
MuSCULOSKELETAL
Conditions
Taithera is a revolutionary nanomedicine targeted drug delivery platform for bone.
ONcology
Targeting primary and metastatic bone cancers.
OSTEOPOROSIS
Taithera can improve low bone density associated with aging.
FRACTURE HEALING
We aim to reduce nonunions, and significantly increase speed of healing for all fractures.
Meet The Team
Seth Harlem
cofounder & CEO
Mo Chen, PhD, MBA
cofounder & Chief Science Officer
Edward Puzas, PhD
Wakenda Tyler, MD
Service Chief, Orthopaedic Oncology
Columbia University Medical Center
Meet The Team
Seth Harlem, MBA
cofounder & CEO
Mo Chen, PhD, MBA
cofounder & Chief Science Officer
Scientific Advisory Board
Monica Fornier, MD
Breast Cancer Oncologist
Memorial Sloan Kettering Cancer Center
Edward Puzas, PhD
Donald and Mary Clark Professor of Orthopaedics
University of Rochester School of Medicine & Dentistry
Edward Puzas, PhD
Donald and Mary Clark Professor of Orthopaedics
University of Rochester School of Medicine & Dentistry
Wakenda Tyler, MD
Chief of Service, Orthopaedic Oncology
Columbia University Medical Center
NEWS & AWARDS
March 2019
Brooklyn, NY
Taithera is pleased to announce the opening of its new laboratory at the Downstate Biotechnology Incubator in Brooklyn, NY.
October 20, 2017
Boston, MA
Taithera Presents at the Pfizer sponsored DDS Technology Soapbox at the Partnership Opportunities in Drug Delivery (PODD) Conference alongside Sonoran Biosciences, Subcuject, BioHealthways, Vesselon, Pendant Biosciences, and Lindy Biosciences.
September 8, 2017
Rochester, NY
Taithera's Technology Featured in ACS Nano
Inventors Dr. Danielle Benoit, Dr. Edward Puzas, et al from the University of Rochester recently had the paper, Fracture-Targeted Delivery of β‐Catenin Agonists via Peptide - Functionalized Nanoparticles Augments Fracture Healing accepted by ACS Nano. It is a great honor to be recognized by such a prestigious journal, and Taithera is proud to be a part of the team.
July 26, 2017
New York, NY
Dr. Mo Chen, Taithera's cofounder and Chief Science Officer published in ACS Nano, a leading nanotechnology journal. Dr. Chen is a corresponding author on the groundbreaking paper, Exosomes Mediate Epithelium-Mesenchyme Crosstalk in Organ Development. ACS Nano is published by the American Chemical Society.
June 23, 2017
Rochester, NY
Taithera, Inc. invited to present at JazzTech 2017 on June 23rd at the University of Rochester. JazzTech 2017 was presented by URVentures and Cranberry Capital, in partnership with Rochester Institute of Technology & New York Medical Angels.
June 20, 2017
San Diego, CA
Taithera, Inc. Wins First Place at the RESI SAN DIEGO 2017 INNOVATION CHALLENGE
Taithera CEO, Seth Harlem (right) and Chief Science Officer, Mo Chen (center) receive First Place at the 2017 RESI Innovation Challenge on June 19th.
June 1, 2017
Taithera, Inc. Selected to Present at The RESI SAN DIEGO 2017 INNOVATION CHALLENGE
April 7, 2017
Taithera CEO, Seth Harlem presented at the 2017 New York City Economic Development Corporation's Entrepreneurship Lab Bio & Health Tech Pitch Day on April 6, 2017.
April 3, 2017
May 16, 2016
PARTNERS
